var data={"title":"Phentolamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Phentolamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6767?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=phentolamine-drug-information\" class=\"drug drug_general\">see &quot;Phentolamine: Drug information&quot;</a> and <a href=\"topic.htm?path=phentolamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Phentolamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45617054\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>OraVerse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209218\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>OraVerse;</li>\n      <li>Rogitine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054927\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Alpha-Adrenergic Blocking Agent, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Extravasation</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diagnostic Agent, Pheochromocytoma</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vasodilator</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444745\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Extravasation of sympathomimetic vasopressors (dopamine, epinephrine, norepinephrine, phenylephrine), treatment:</b> Limited data available: SubQ: Infiltrate area of extravasation with a small amount (eg, 1 mL given in 0.1 to 0.2 mL aliquots) of a 0.5 mg/mL solution within 12 hours of extravasation (Flemmer 1993; Siwy 1987; Subhani 2001; Thigpen 2007); concentrations  up to 1 mg/mL have been used in infants and have also been suggested in neonates although data is very limited and based on clinical experience and institutional protocols (Beall 2013; Hill 1991; MacCara 1983; Montgomery 1999). Total dose required depends on the size of extravasation; dose may be repeated if required. One case report administered a total of 7.5 mL of a 0.5 mg/mL solution to a 2 day old, 37 week GA neonate (Siwy 1987). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054921\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=phentolamine-drug-information\" class=\"drug drug_general\">see &quot;Phentolamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation of sympathomimetic vasopressors, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:  <i>Norepinephrine extravasation:</i> Children and Adolescents: Local infiltration: Infiltrate area of extravasation with a small amount of a 0.5 to 1 mg/mL solution as soon as extravasation is noted but within 12 hours of extravasation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing:  <i>Extravasation of  dopamine, epinephrine, norepinephrine, phenylephrine:</i> Limited data available: Infants, Children, and Adolescents: SubQ: Infiltrate area of extravasation with a small amount (eg, 1 mL given in 0.2 mL aliquots) of a 0.5 to 1 mg/mL solution within 12 hours of extravasation (Flemmer 1993; Hill 1991; MacCara 1983; Montgomery 1999). Total dose required depends on the size of extravasation; dose may be repeated if required. When reported, the total dose needed was 1 to 5 mL of a 1 mg/mL solution; however, other concentrations could be used (Montgomery 1999). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnosis of pheochromocytoma (phentolamine blocking test): Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children and Adolescents:  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available: Children and Adolescents: IV:  0.05 to 0.1 mg/kg/dose, maximum single dose: 5 mg (Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertensive episodes associated with pheochromocytoma, prevention and treatment: Note:</b> In the perioperative period, the use of other agents may be preferred due to slow onset of action and prolonged duration of phentolamine in comparison to the other agents (eg, nitroprusside) (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preoperative:</i> Children and Adolescents: IM, IV: 1 mg given 1 to 2 hours before surgery and repeat if needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Intraoperative:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Children and Adolescents: IV: 1 mg as indicated to prevent or control paroxysms of hypertension, tachycardia, respiratory depression, seizure, or other effects associated with epinephrine intoxication resulting from tumor manipulation </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: Limited data available: Infants, Children, and Adolescents: IV: 0.05 to 0.1 mg/kg/dose (Cot&eacute; 2013). <b>Note:</b> Usual adult dose is 5 mg/dose (Miller 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse): Note:</b> Dose is based upon the number of cartridge(s) of local anesthetic administered; location and administration technique (infiltration or block injection) should be the same as used for local anesthetic administration. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years weighing &ge;15 kg and Adolescents: Submucosal oral injection: Infiltration or block technique:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Amount of Local Anesthetic Administered</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose of OraVerse</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>/<sub>4</sub> Cartridge</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>/<sub>4</sub> Cartridge (0.1 mg)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>/<sub>2</sub> Cartridge</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>/<sub>2</sub> Cartridge (0.2 mg)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 Cartridge</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 Cartridge (0.4 mg)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 Cartridges</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 Cartridges (0.8 mg)</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum dose: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to &lt;30 kg: 0.2 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;30 kg: 0.8 mg/dose; <b>Note:</b> A dose of &gt;0.4 mg has not been studied in children &lt;4 years </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation of norepinephrine, management (manufacturer's labeling):</b> Local infiltration: Inject 5 to 10 mg (diluted in 10 mL 0.9% sodium chloride) into extravasation area (as soon as extravasation is noted but within 12 hours of extravasation)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extravasation of sympathomimetic vasopressors, management:</i> Infiltrate extravasation site with 5 to 10 mg (diluted in 10 to 15 mL 0.9% sodium chloride) as soon as possible after extravasation (Peberdy 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnosis of pheochromocytoma (phentolamine-blocking test): Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis: IM, IV: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertensive episodes associated with pheochromocytoma, prevention and management: Note:</b> In the perioperative period, the use of other agents may be preferred due to slow onset of action and prolonged duration of phentolamine in comparison to the other agents (eg, nitroprusside) (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preoperative:</i> IM, IV: 5 mg given 1 to 2 hours before surgery and repeat if needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intraoperative:</i> IV: Administer 5 mg as indicated to prevent or control paroxysms of hypertension, tachycardia, respiratory depression, seizure, or other effects associated with epinephrine intoxication resulting from tumor manipulation or other stressor (eg, intubation) (Miller 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse):</b> Infiltration or block technique: Submucosal oral injection: <b>Note:</b> Dose is based upon the number of cartridges of local anesthetic administered. Infiltration or block injection: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.1 mg if one-quarter cartridge of anesthesia was administered</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.2 mg if one-half cartridge of anesthesia was administered</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.4 mg if 1 cartridge of anesthesia was administered</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.8 mg if 2 cartridges of anesthesia were administered</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209199\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (1 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as mesylate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">OraVerse: 0.4 mg/1.7 mL (1.7 mL) [contains edetate disodium; dental cartridge]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209183\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054931\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Powder for injection: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation treatment:</b> SubQ: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula; elevate extremity. Infiltrate area of extravasation with multiple small injections of a diluted solution; use 25- or 30-gauge  <sup>1</sup>/<sub>2</sub>-inch needles; insert at a 15&deg; angle, bevel up and change needle between each skin entry (Hill 1991; Siwy 1987).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pheochromocytoma diagnosis (Phentolamine block test):</b> IM, IV: Patient should be supine throughout test, preferable in a quiet, dark room. Blood pressure should be monitored every 10 minutes for at least 30 minutes, delay phentolamine administration until after blood pressure is stable (at an untreated, hypertensive level). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: After IM injection, monitor blood pressure every 5 minutes for 35 to 40 minutes. Blood pressure drops to target parameters - within 20 minutes are considered positive (see <b>Note</b>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Inject rapidly (after venous response to venipuncture has subsided); then monitor blood pressure immediately after injection, every 30 seconds for 3 minutes, then every minute for 7 minutes. Maximum response is generally achieved within 2 minutes; duration may last 15 to 30 minutes (although return to prior blood pressure may be sooner). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> A drop in blood pressure &ge;35 mm Hg (systolic) and &ge;25 mm Hg (diastolic) is considered a positive response. If blood pressure is elevated, unchanged, or decrease is &lt;35 mm Hg (systolic) and &lt;25 mm Hg (diastolic), then response is negative. Confirm positive response with other diagnostic measure. Negative responses do not exclude a pheochromocytoma diagnosis, particularly in patients with paroxysmal hypertension where an incidence of false negatives is high.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pheochromocytoma-associated hypertensive episode:</b> IM, IV: Administer 1 to 2 hours prior to surgery and repeat during surgery (as rapid IV injection) if necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3145034\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for injection: Store intact vials 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Reconstituted solution should be used immediately after preparation (per manufacturer). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for injection (OraVerse): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); brief excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from direct heat and light. Do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054930\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for injection: Diagnosis of pheochromocytoma via the phentolamine-blocking test (see <b>Note</b>);  prevention and management of hypertensive episodes associated with pheochromocytoma resulting from stress or manipulation during the perioperative period; prevention and treatment of dermal necrosis/sloughing after extravasation of norepinephrine (All indications: FDA approved in children and adults); has also been used for management of extravasations of other vasopressors including dobutamine, dopamine, epinephrine, and phenylephrine) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dental cartridge (OraVerse): Reversal of soft tissue (lip, tongue) anesthesia and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor (FDA approved in ages &ge;3 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209252\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Phentolamine may be confused with phentermine, Ventolin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Regitine may be confused with Reglan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209249\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia (OraVerse), cerebrovascular occlusion, hypertension (OraVerse), hypotension, myocardial infarction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Cerebrovascular spasm, headache (OraVerse), mouth pain (OraVerse), paresthesia (OraVerse; mild, transient) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Facial swelling (OraVerse), pruritus (OraVerse) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (OraVerse), nausea, upper abdominal pain (OraVerse), vomiting (OraVerse)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site (OraVerse)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Jaw pain (OraVerse)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Postinjection pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Cardiac arrhythmia, orthostatic hypotension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209205\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to phentolamine, any component of the formulation, or related compounds; MI (or history of MI), coronary insufficiency, angina, or other evidence suggestive of coronary artery disease (excluding OraVerse)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Hypotension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209187\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: MI, cerebrovascular spasm, and cerebrovascular occlusion have been reported following administration, usually associated with hypotensive episodes producing shock-like states. Tachycardia and cardiac arrhythmias may occur. Use with caution in patients with a history of cardiovascular disease. Discontinue if symptoms of angina occur or worsen. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: The use of phentolamine as a blocking agent in the screening of patients with hypertension has predominantly been replaced with urinary/biochemical assays; phentolamine use should be reserved for situations where additional confirmation is necessary and after risks associated with use have been considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299867\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209192\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12700&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209195\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13823798\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some oral animal reproduction studies. Diagnosing and treating pheochromocytoma is critical for favorable maternal and fetal outcomes (Schenker 1971; Schenker 1982). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054926\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate, orthostasis; treatment of extravasation: site of extravasation, skin color, local perfusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209186\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitively blocks alpha-adrenergic receptors (nonselective) to produce brief antagonism of circulating epinephrine and norepinephrine to reduce hypertension caused by alpha effects of these catecholamines and minimizes tissue injury due to extravasation of these and other sympathomimetic vasoconstrictors (eg, dopamine, phenylephrine); also has a positive inotropic and chronotropic effect on the heart thought to be due to presynaptic alpha-2 receptor blockade which results in release of presynaptic norepinephrine (Hoffman 1980)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">OraVerse: Causes vasodilation and increased blood flow in injection area via alpha-adrenergic blockade to accelerate reversal of soft tissue anesthesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209204\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IM: 15 to 20 minutes; IV: 1 to 2 minutes (Chobanian 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: OraVerse: 10 to 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IM: 30 to 45 minutes; IV: 10 to 30 minutes (Chobanian 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 19 minutes; Submucosal injection: ~2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~13% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597873\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">OraVerse C<sub>max</sub> ~3.5-fold higher in children weighing 15 to 30 kg compared with children weighing &gt;30 kg. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054936\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Injection contains mannitol 25 mg/vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323680\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Phentolamine Mesylate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $510.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038766\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fentanor (IN);</li>\n      <li>Oraverse (ES);</li>\n      <li>Phentolmin (KR);</li>\n      <li>Phentosol (IN, LK);</li>\n      <li>Regitin (CH, DK, HN);</li>\n      <li>Regitina (AR, BR, VE);</li>\n      <li>Regitine (BE, CN, EG, GR, HK, HU, IL, KW, LU, NL, NZ, QA, SA);</li>\n      <li>Rogitine (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Beall V, Hall B, Mulholland JT, Gephart SM. Neonatal Extravasation. <i>NAINR</i>. 2013&#894;13(4):189-195. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. <i>JAMA</i>. 2003;289(19):2560-2572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/12748199 /pubmed\" target=\"_blank\" id=\"12748199 \">12748199 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper BE, &quot;High-Dose Phentolamine for Extravasation of Pressors,&quot; <i>Clin Pharm</i>, 1989, 8(10):689.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/2805622/pubmed\" target=\"_blank\" id=\"2805622\">2805622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cote CJ, Lerman J,  Anderson B, eds.<i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Elsevier; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flemmer L and Chan JS, &quot;A Pediatric Protocol for Management of Extravasation Injuries,&quot;  <i>Pediatr Nurs</i>, 1993, 19(4):355-8, 424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/8414723/pubmed\" target=\"_blank\" id=\"8414723\">8414723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill JM. Phentolamine mesylate: the antidote for vasopressor extravasation. <i>Crit Care Nurse</i>. 1991;11(10):58-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/1720079 /pubmed\" target=\"_blank\" id=\"1720079 \">1720079 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoff JV, Peatty PA, and Wade JL, &ldquo;Dermal Necrosis From Dobutamine,&rdquo; <i>N Engl J Med</i>, 1979, 300(22):1280. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/431702/pubmed\" target=\"_blank\" id=\"431702\">431702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoffman BB, Lefkowitz RJ. Alpha-adrenergic receptor subtypes. <i>N Engl J Med</i>. 1980;302(25):1390-1396. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME, &ldquo;Extravasation: A Hazard of Intravenous Therapy,&rdquo; <i>Drug Intell Clin Pharm</i>, 1983, 17(10):713-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD. <i>Miller&rsquo;s Anesthesia</i>. 7th ed. Philadelphia PA: Churchill Livingstone; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery LA, Hanrahan K, Kottman K, Otto A, Barrett T, Hermiston B. Guideline for i.v. infiltrations in pediatric patients.<i> Pediatr Nurs</i>. 1999;25(2):167-169, 173-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/10532013 /pubmed\" target=\"_blank\" id=\"10532013 \">10532013 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    OraVerse injection (phentolamine) [prescribing information]. Louisville, CO: Septodent, Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <b>Circulation</b>. 2010;122(18 Suppl 3):S768-S786.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/20956225 /pubmed\" target=\"_blank\" id=\"20956225 \">20956225 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phentolamine powder for solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/24420913 /pubmed\" target=\"_blank\" id=\"24420913 \">24420913 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schenker JG and Chowers I, &quot;Pheochromocytoma and Pregnancy. Review of 89 Cases,&quot; <i>Obstet Gynecol Surv</i>, 1971, 26(11):739-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/5173093/pubmed\" target=\"_blank\" id=\"5173093\">5173093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schenker JG and Granat M, &quot;Phaeochromocytoma and Pregnancy - An Updated Appraisal,&quot; <i>Aust N Z J Obstet Gynaecol</i>, 1982, 22(1):1-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/6954937/pubmed\" target=\"_blank\" id=\"6954937\">6954937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siwy BK and Sadove AM, &quot;Acute Management of Dopamine Infiltration Injury With Regitine,&quot; <i>Plast Reconstr Surg</i>, 1987, 80(4):610-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/3659173/pubmed\" target=\"_blank\" id=\"3659173\">3659173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Subhani M, Sridhar S, and DeCristofaro JD, &quot;Phentolamine Use in a Neonate for the Prevention of Dermal Necrosis Caused by Dopamine: A Case Report,&quot; <i>J Perinatol</i>, 2001, 21(5):324-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/11536027/pubmed\" target=\"_blank\" id=\"11536027\">11536027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thigpen JL, &quot;Peripheral Intravenous Extravasation: Nursing Procedure for Initial Treatment,&quot;<i> Neonatal Netw</i>, 2007, 26(6):379-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-pediatric-drug-information/abstract-text/18069429/pubmed\" target=\"_blank\" id=\"18069429\">18069429</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12700 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45617054\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F209218\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054927\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444745\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054921\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F209199\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F209183\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054931\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3145034\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054930\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F209252\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F209249\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F209205\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F209187\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299867\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F209192\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F209195\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13823798\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054926\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F209186\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F209204\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597873\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1054936\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323680\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038766\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12700|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=phentolamine-drug-information\" class=\"drug drug_general\">Phentolamine: Drug information</a></li><li><a href=\"topic.htm?path=phentolamine-patient-drug-information\" class=\"drug drug_patient\">Phentolamine: Patient drug information</a></li></ul></div></div>","javascript":null}